Hitachi to Develop 'Confidential AI Platform' to Accelerate Open Innovation in AI Drug Discovery. Full-Scale Co-Creation with MOLCURE Toward Service Provision
Hitachi and MOLCURE have fully launched their co-creation to develop a 'Confidential AI Platform' to accelerate AI-driven drug discovery for biopharmaceuticals.
📋 Article Processing Timeline
- 📰 Published: April 16, 2026 at 11:00
- 🔍 Collected: April 16, 2026 at 11:31 (31 min after Published)
- 🤖 AI Analyzed: April 19, 2026 at 03:48 (64h 16m after Collected)
MOLCURE was established in 2013 with the aim of building the world's most superior biopharmaceutical design platform. Its AI drug discovery platform is built upon a proprietary large language model and high-quality experimental data obtained from its in-house bio-laboratory, enabling the design of diverse and high-quality antibodies and peptides. By partnering with innovative pharmaceutical companies, we contribute to the development of medicines that improve the lives of patients worldwide.